Generalizability of the REDUCE-IT trial and cardiovascular outcomes associated with hypertriglyceridemia among patients potentially eligible for icosapent ethyl therapy: An analysis of the REduction of Atherothrombosis for Continued Health (REACH) registry.

MLA

Picard, Fabien, et al. “Generalizability of the REDUCE-IT Trial and Cardiovascular Outcomes Associated with Hypertriglyceridemia among Patients Potentially Eligible for Icosapent Ethyl Therapy: An Analysis of the REduction of Atherothrombosis for Continued Health (REACH) Registry.” International Journal of Cardiology, vol. 340, Oct. 2021, pp. 96–104. EBSCOhost, https://doi.org/10.1016/j.ijcard.2021.08.031.

APA

Picard, F., Bhatt, D. L., Ducrocq, G., Ohman, E. M., Goto, S., Eagle, K. A., Wilson, P. W. F., Smith, S. C., Jr, Elbez, Y., & Steg, P. G. (2021). Generalizability of the REDUCE-IT trial and cardiovascular outcomes associated with hypertriglyceridemia among patients potentially eligible for icosapent ethyl therapy: An analysis of the REduction of Atherothrombosis for Continued Health (REACH) registry. International Journal of Cardiology, 340, 96–104. https://doi.org/10.1016/j.ijcard.2021.08.031

Chicago

Picard, Fabien, Deepak L Bhatt, Grégory Ducrocq, E Magnus Ohman, Shinya Goto, Kim A Eagle, Peter W F Wilson, Sidney C Smith Jr, Yedid Elbez, and Philippe Gabriel Steg. 2021. “Generalizability of the REDUCE-IT Trial and Cardiovascular Outcomes Associated with Hypertriglyceridemia among Patients Potentially Eligible for Icosapent Ethyl Therapy: An Analysis of the REduction of Atherothrombosis for Continued Health (REACH) Registry.” International Journal of Cardiology 340 (October): 96–104. doi:10.1016/j.ijcard.2021.08.031.